From Pregnancy to Preeclampsia: A Key Role for Estrogens

Endocrine Reviews

Volumn 38, Issue 2, 2017, Pages 123-144

  Berkane, Nadia ^a,b   Liere, Philippe ^b   Oudinet, Jean Paul ^b   Hertig, Alexandre ^c,d,e   Lefevre, Guillaume ^c,d   Pluchino, Nicola ^a   Schumacher, Michael ^b   Chabbert Buffet, Nathalie ^c,d,f  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Hopital   (France)

^f CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; ANGIOGENIC FACTOR; CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; CORTICOTROPIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTETROL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; G PROTEIN COUPLED RECEPTOR 30; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MICRORNA; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PRASTERONE; PROSTACYCLIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFOTRANSFERASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; FETUS MORTALITY; GENE OVEREXPRESSION; HIGH THROUGHPUT ANALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; MATERNAL MORTALITY; NATURAL KILLER CELL; OBESITY; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; STEROIDOGENESIS; SYNCYTIOTROPHOBLAST; TROPHOBLAST; UTERUS BLOOD FLOW; VASCULAR SMOOTH MUSCLE; VASODILATATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ESTROGENS; FEMALE; HUMANS; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY;

EID: 85025104854     PISSN: 0163769X     EISSN: 19457189     Source Type: Journal    
DOI: 10.1210/er.2016-1065     Document Type: Review

References (288)

1. Savitz DA, Danilack VA, Engel SM, Elston B, Lipkind HS. Descriptive epidemiology of chronic hypertension, gestational hypertension, and preeclampsia in New York State, 1995-2004. Matern Child Health J. 2014;18(4):829-838.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066-1074.
3. Kuklina EV, Ayala C, CallaghanWM.Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113(6):1299-1306.
4. Berkane N. Définitions et conséquences des hypertensions artérielles de la grossesse [Gestational hypertensions: definitions and consequences in outcome of pregnancy]. Ann Fr Anesth Reanim. 2010;29(3):e1-e6.
5. Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost. 2007;13(3):285-291.
6. Catarino C, Santos-Silva A, Belo L, Rocha-Pereira P, Rocha S, Patrício B, Quintanilha A, Rebelo I. Inflammatory disturbances in preeclampsia: relationship between maternal and umbilical cord blood. J. Pregnancy 2012;2012:1-10.
7. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499-506.
8. Zhou Y, McMaster M, WooK, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160(4):1405-1423.
9. Hertig A, Berkane N, Lefevre G, Toumi K, Marti H-P, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50(9):1702-1703.
10. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-683.
11. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658.
12. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188(1): 177-182.
13. Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, Schaaps J-P, Cabrol D, Frankenne F, Foidart J-M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88(11):5555-5563.
14. Tsatsaris V, Goffin F, Foidart JM. Circulating angiogenic factors and preeclampsia. N Engl J Med. 2004;350(19):2003-2004, author reply 2003-2004.
15. Redman CWG, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009;30 Suppl A:S38-42.
16. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-1594.
17. Labarrere CA. Acute atherosis. A histopathological hallmark of immune aggression?. Placenta. 1988;9(1):95-108.
18. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000;4(4):441-458.
19. Chen G, R Wilson, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol. 1996;104(1):154-159.
20. Lau SY, Guild S-J, Barrett CJ, Chen Q, McCowan L, Jordan V, Chamley LW. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am J Reprod Immunol. 2013;70(5): 412-427.
21. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol. 1995;102(1):20-25.
22. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. [Pre-eclampsia: a disorders of the endothelial cells?.] Gyn¨akol. 1992;25:2-6.
23. Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol. 1988;159(4):908-914.
24. Rosenfeld CR, Rivera R. Circulatory responses to systemic infusions of estrone and estradiol-17alpha in nonpregnant, oophorectomized ewes. Am J Obstet Gynecol. 1978;132(4):442-448.
25. Caulin-Glaser T, García-Cardeña G, Sarrel P, Sessa WC, Bender JR. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997;81(5):885-892.
26. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001;276(5):3459-3467.
27. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002;105(11): 1368-1373.
28. Cullinan-Bove K, Koos RD. Vascular endothelial growth factor/ vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 1993;133(2):829-837.
29. Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J Endocrinol. 2006;188(1):91-99.
30. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 1996;81(8): 3112-3118.
31. Johnson ML, Grazul-Bilska AT, Redmer DA, Reynolds LP. Effects of estradiol-17beta on expression of mRNA for seven angiogenic factors and their receptors in the endometrium of ovariectomized (OVX) ewes. Endocrine. 2006;30(3):333-342.
32. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the expression of tumor necrosis factor alphamRNAin phorbol esterstimulated human monocytic THP-1 cells. Lymphokine Cytokine Res. 1994;13(6):377-382.
33. Notation AD, Tagatz GE. Unconjugated estriol and 15alphahydroxyestriol in complicated pregnancies. Am J Obstet Gynecol. 1977;128(7):747-756.
34. Rahman SA, Hingorani V, Laumas KR. Biosynthesis of oestrogens and their inter-conversion in human placentae from normal and toxaemic pregnancies. Clin Endocrinol (Oxf). 1975;4(4):333-341.
35. Rosing U, Carlström K. Serum levels of unconjugated and total oestrogens and dehydroepiandrosterone, progesterone and urinary oestriol excretion in pre-eclampsia. Gynecol Obstet Invest. 1984;18(4):199-205.
36. Zamudio S, Leslie KK, White M, Hagerman DD, Moore LG. Low serum estradiol and high serum progesterone concentrations characterize hypertensive pregnancies at high altitude. J Soc Gynecol Investig. 1994;1(3):197-205.
37. Hertig A, Liere P, Chabbert-Buffet N, Fort J, Pianos A, Eychenne B, Cambourg A, Schumacher M, Berkane N, Lefevre G, Uzan S, Rondeau E, Rozenberg P, Rafestin-Oblin M-E. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol. 2010;203(5):477.e1-477.e9.
38. Jobe SO, Tyler CT, Magness RR. Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. Hypertension. 2013;61(2):480-487.
39. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98(10): 3971-3973.
40. Palmer AE, London WT, Sly DL, Rice JM. Spontaneous preeclamptic toxemia of pregnancy in the patas monkey (Erythrocebus patas). Lab Anim Sci. 1979;29(1):102-106.
41. Krugner-Higby L, Luck M, Hartley D, Crispen HM, Lubach GR, Coe CL. High-risk pregnancy in rhesus monkeys (Macaca mulatta): a case of ectopic, abdominal pregnancy with birth of a live, term infant, and a case of gestational diabetes complicated by pre-eclampsia. J Med Primatol. 2009;38(4):252-256.
42. Hennessy A, Gillin AG, Painter DM, Kirwan PJ, Thompson JF, Horvath JS. Evidence for preeclampsia in a baboon pregnancy with twins. Hypertens Pregnancy. 2009;16(2):223-228.
43. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol. 2005;3:56.
44. Genbacev OD, Prakobphol A, Foulk RA, Krtolica AR, Ilic D, Singer MS, Yang Z-Q, Kiessling LL, Rosen SD, Fisher SJ. Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science. 2003;299(5605):405-408.
45. Challier J-C, Uzan S. [The human placenta and its pathologies: focus on oxygen] Med Sci (Paris). 2003;19(11):1111-1120.
46. Merviel P, Challier JC, Carbillon L, Foidart JM, Uzan S. The role of integrins in human embryo implantation. Fetal Diagn Ther. 2001;16(6):364-371.
47. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J Clin Invest. 1997;99(9):2139-2151.
48. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update. 2012;18(4):458-471.
49. Whitley GSJ, Cartwright JE. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. J Anat. 2009;215(1):21-26.
50. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun. 2002;291(4):908-914.
51. Wheeler T, Elcock CL, Anthony FW. Angiogenesis and the placental environment. Placenta. 1995;16(3):289-296.
52. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27(9-10):939-958.
53. Goldman-Wohl D, Yagel S. Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol. 2002;187(1-2):233-238.
54. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in preeclamptic pregnancies. Br J Obstet Gynaecol. 1998;105(6): 632-640.
55. Tse C, Lefevre G, Berkane N, Flahault A, Toumi K, Brault D, Capeau J, Uzan S. Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia. Clin Chem Lab Med. 2004;42(2):142-146.
56. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y.Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology. 2004;145(11): 4838-4845.
57. Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005;26(2-3):210-217.
58. Hofmann S, Grasberger H, Jung P, Bidlingmaier M, Vlotides J, Janssen OE, Landgraf R. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VEcadherin expression. Eur J Med Res. 2002;7(4):171-176.
59. Carter AM, Enders AC, Pijnenborg R. The role of invasive trophoblast in implantation and placentation of primates. Philos Trans R Soc Lond B Biol Sci. 2015;370(1663):20140070.
60. Devroey P, Camus M, Palermo G, Smitz J, Van Waesberghe L, Wisanto A, Wijbo I, Van Steirteghem AC. Placental production of estradiol and progesterone after oocyte donation in patients with primary ovarian failure. Am J Obstet Gynecol. 1990;162(1): 66-70.
61. Castracane VD, Goldzieher JW. Timing of the luteal-placental shift in the baboon (Papio cynocephalus). Endocrinology. 1986; 118(2):506-512.
62. Levitz M, Young BK. Estrogens in pregnancy. Vitam Horm. 1977; 35:109-147.
63. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol. 2009;114(6):1326-1331.
64. Oakey RE. The progressive increase in estrogen production in human pregnancy: an appraisal of the factors responsible. Vitam Horm. 1970;28:1-36.
65. Tang Z, Tadesse S, Norwitz E, Mor G, Abrahams VM, Guller S. Isolation of hofbauer cells from human term placentas with high yield and purity. Am J Reprod Immunol. 2011;66(4):336-348.
66. Schmidt M, Kreutz M, Löffler G, Schölmerich J, Straub RH. Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol. 2000;164(2):161-169.
67. Escobar JC, Patel SS, Beshay VE, Suzuki T, Carr BR. The human placenta expresses CYP17 and generates androgens de novo. J Clin Endocrinol Metab. 2011;96(5):1385-1392.
68. Pion R, Jaffe R, Eriksson G, Wiqvist N, Diczfalusy E. Studies on the metabolism of C-21 steroids in the human foetoplacental unit. I. Formation of a beta-unsaturated 3-ketones in midterm placentas perfused in situ with pregnenolone and 17-alpha-hydroxypregnenolone. Acta Endocrinol (Copenh). 1965;48:234-248.
69. Siiteri PK, MacDonald PC. Placental estrogen biosynthesis during human pregnancy. J Clin Endocrinol Metab. 1966;26(7): 751-761.
70. Falany CN, Wheeler J, Oh TS, Falany JL. Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 1994;48(4):369-375.
71. Siiteri PK. The continuing saga of dehydroepiandrosterone (DHEA). J Clin Endocrinol Metab. 2005;90(6):3795-3796.
72. PeterM, Dörr HG, SippellWG. Changes in the concentrations of dehydroepiandrosterone sulfate and estriol in maternal plasma during pregnancy: a longitudinal study in healthy women throughout gestation and at term. Horm Res. 1994;42(6): 278-281.
73. Salido EC, Yen PH, Barajas L, Shapiro LJ. Steroid sulfatase expression in human placenta: immunocytochemistry and in situ hybridization study. J Clin Endocrinol Metab. 1990;70(6): 1564-1567.
74. Mizuno M, Lobotsky J, Lloyd CW, Kobayashi T, Murasawa Y. Plasma androstenedione and testerone during pregnancy and in the newborn. J Clin Endocrinol Metab. 1968;28(8):1133-1142.
75. Rivarola MA, Forest MG, Migeon CJ. Testosterone, androstenedione and dehydroepiandrosterone in plasma during pregnancy and at delivery: concentration and protein binding. J Clin Endocrinol Metab. 1968;28(1):34-40.
76. Ruder HJ, Loriaux L, Lipsett MB. Estrone sulfate: production rate and metabolism in man. J Clin Invest. 1972;51(4):1020-1033.
77. Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regulation of steroid action by sulfation and desulfation. Endocr Rev. 2015;36(5):526-563.
78. Calzada-Mendoza CC, Sánchez EC, Campos RR, Becerril AM, Madrigal EB, Sierra AR, Mendez EB, Ocharán EH, Herrera NG, Ceballos-Reyes G. Differential aromatase (CYP19) expression in human arteries from normal and neoplasic uterus: an immunohistochemical and in situ hybridization study. Front Biosci. 2006; 11:389-393.
79. BonenfantM, Provost PR, Drolet R, Tremblay Y. Localization of type 1 17beta-hydroxysteroid dehydrogenase mRNA and protein in syncytiotrophoblasts and invasive cytotrophoblasts in the human term villi. J Endocrinol. 2000;165(2):217-222.
80. Albrecht ED, Pepe GJ. Placental steroid hormone biosynthesis in primate pregnancy. Endocr Rev. 1990;11(1):124-150.
81. Yoshida N, Osawa Y. Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. Biochemistry. 1991;30(12):3003-3010.
82. MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell JMC, Davies E. Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol (Oxf). 2008;69(6):848-854.
83. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev. 1995;16(5): 608-648.
84. Husen B, Adamski J, Brüns A, Deluca D, Fuhrmann K, M¨oller G, Schwabe I, Einspanier A. Characterization of 17betahydroxysteroid dehydrogenase type 7 in reproductive tissues of the marmoset monkey. Biol Reprod. 2003;68(6):2092-2099.
85. Milewich L, MacDonald PC, Carr BR. Estrogen 16 alphahydroxylase activity in human fetal tissues. J Clin Endocrinol Metab. 1986;63(2):404-406.
86. Zbella EA, Ilekis J, Scommegna A, Benveniste R. Competitive studies with dehydroepiandrosterone sulfate and 16 alphahydroxydehydroepiandrosterone sulfate in cultured human choriocarcinoma JEG-3 cells: effect on estrone, 17 beta-estradiol, and estriol secretion. J Clin Endocrinol Metab. 1986;63(3):751-757.
87. Cantineau R, Kremers P, De Graeve J, Gielen JE, Lambotte R. 15- and 16-hydroxylations of androgens and estrogens in the human fetal liver: a critical step in estetrol biosynthesis. J Steroid Biochem. 1985;22(2):195-201.
88. Gurpide E, Schwers J, Welch MT, Vande Wiele RL, Lieberman S. Fetal and maternal metabolism of estradiol during pregnancy. J Clin Endocrinol Metab. 1966;26(12):1355-1365.
89. Holinka CF, Diczfalusy E, Coelingh Bennink HJT. Estetrol: a unique steroid in human pregnancy. J Steroid Biochem Mol Biol. 2008;110(1-2):138-143.
90. Schwers J, Eriksson G, Diczfalusy E. 15alpha-hydroxylation: a new pathway of estrogen metabolism in the human fetus and newborn. Biochim Biophys Acta. 1965;100:313-316.
91. Benassi L, Alfieri L, Debiasi D, Trentadue R. Unconjugated estetrol in normal pregnancy. Clin Exp Obstet Gynecol. 1982; 9(4):243-245.
92. Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, Drougard A, Rajan S, Laine M, Milon A, Muller I, Henrion D, Adlanmerini M, Valéra M-C, Gompel A, Gerard C, Péqueux C, Mestdagt M, Raymond-Letron I, Knauf C, Ferriere F, Valet P, Gourdy P, Katzenellenbogen BS, Katzenellenbogen JA, Lenfant F, Greene GL, Foidart J-M, Arnal J-F. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328-1346.
93. Pluchino N, Santoro AN, Casarosa E, Giannini A, Genazzani A, Russo M, Russo N, Petignat P, Genazzani AR. Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats. J Steroid Biochem Mol Biol. 2014;143: 285-290.
94. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart J-M, Gemzell-Danielsson K. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016;91:93-100.
95. Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, Jackson EK. CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension. 2003;41(3 Pt 2):807-813.
96. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004; 308(2):403-409.
97. Jobe SO, Ramadoss J, Koch JM, Jiang Y, Zheng J, Magness RR. Estradiol-17beta and its cytochrome P450- and catechol-Omethyltransferase- derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension. 2010;55(4): 1005-1011.
98. Stice SL, Ford SP, Rosazza JP, Van Orden DE. Interaction of 4- hydroxylated estradiol and potential-sensitive Ca2+ channels in altering uterine blood flow during the estrous cycle and early pregnancy in gilts. Biol Reprod. 1987;36(2):369-375.
99. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144(8):3382-3398.
100. Casey ML, MacDonald PC. Characterization of catechol-Omethyltransferase activity in human uterine decidua vera tissue. Am J Obstet Gynecol. 1983;145(4):453-457.
101. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90(1):5-22.
102. Miki Y, Nakata T, Suzuki T, Darnel AD, Moriya T, Kaneko C, Hidaka K, Shiotsu Y, Kusaka H, Sasano H. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab. 2002;87(12): 5760-5768.
103. Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song W-C. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11(2):153-159.
104. Aitio A. UDPglucuronosyltransferase of the human placenta. Biochem Pharmacol. 1974;23(15):2203-2205.
105. Paakki P, Stockmann H, Kantola M, Wagner P, Lauper U, Huch R, Elovaara E, Kirkinen P, Pasanen M. Maternal drug abuse and human term placental xenobiotic and steroid metabolizing enzymes in vitro. Environ Health Perspect. 2000;108(2):141-145.
106. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-282.
107. Yin G, Zhu X, Guo C, Yang Y, Han T, Chen L, Yin W, Gao P, Zhang H, Geng J, Wang J, Liang L. Differential expression of estradiol and estrogen receptor a in severe preeclamptic pregnancies compared with normal pregnancies. Mol Med Rep. 2013; 7(3):981-985.
108. Bussen S, Bussen D. Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome. Arch Gynecol Obstet. 2011;284(3):551-557.
109. Salas SP, Marshall G, Gutiérrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension. 2006; 47(2):203-208.
110. Açikgöz S, Bayar UO, Can M, Güven B, Mungan G, Doǧan S, Sümbüloǧ lu V. Levels of oxidized LDL, estrogens, and progesterone in placenta tissues and serum paraoxonase activity in preeclampsia. Mediators Inflamm. 2013;2013:862982.
111. Zhang Y, Wang T, Shen Y, Wang X, Baker PN, Zhao A. 2- Methoxyestradiol deficiency is strongly related to hypertension in early onset severe pre-eclampsia. Pregnancy Hypertens. 2014; 4(3):215-219.
112. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2- methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453(7198):1117-1121.
113. Pérez-Sepúlveda A, Torres MJ, Valenzuela FJ, Larraín R, Figueroa- Diesel H, Galaz J, Nien JK, Serra R, Michea L, Illanes SE. Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. Prenat Diagn. 2012;32(11):1053-1058.
114. Pertegal M, Fenoy FJ, Hernández M, Mendiola J, Delgado JL, Bonacasa B, Corno A, López B, Bosch V, Hernández I. Fetal Val108/158Met catechol-O-methyltransferase (COMT) polymorphism and placental COMT activity are associated with the development of preeclampsia. Fertil Steril. 2016;105(1):134-43. e1, 3.
115. Shen Z, WuY, Chen X, Chang X, Zhou Q, Zhou J, Ying H, Zheng J, Duan T, Wang K. Decreased maternal serum 2-methoxyestradiol levels are associated with the development of preeclampsia. Cell Physiol Biochem. 2014;34(6):2189-2199.
116. Seol H-J, Cho G-J, Oh M-J, Kim H-J. 2-methoxyoestradiol levels and placental catechol-O-methyltransferase expression in patients with late-onset preeclampsia. Arch Gynecol Obstet. 2013;287(5): 881-886.
117. Sharifzadeh F, Kashanian M, Fatemi F. A comparison of serum androgens in pre-eclamptic and normotensive pregnant women during the third trimester of pregnancy. Gynecol Endocrinol. 2012;28(10):834-836.
118. Martin JD, H¨ahnel ME, H¨ahnel R. Plasma androstenedione in normotensive and hypertensive pregnancy. Steroids. 1986;48(5- 6):315-329.
119. Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA. 1993;90(23): 11312-11316.
120. Kragie L. Aromatase in primate pregnancy: a review. Endocr Res. 2002;28(3):121-128.
121. Toda K, Simpson ER, Mendelson CR, Shizuta Y, Kilgore MW. Expression of the gene encoding aromatase cytochrome P450 (CYP19) in fetal tissues. Mol Endocrinol. 1994;8(2):210-217.
122. Nakajin S, Shinoda M, Hall PF. Purification to homogeneity of aromatase from human placenta. BiochemBiophys Res Commun. 1986;134(2):704-710.
123. Kamat A, Alcorn JL, Kunczt C, Mendelson CR. Characterization of the regulatory regions of the human aromatase (P450arom) gene involved in placenta-specific expression. Mol Endocrinol. 1998;12(11):1764-1777.
124. Kumar P, Kamat A, Mendelson CR. Estrogen receptor alpha (Eralpha) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta. Mol Endocrinol. 2009;23(6):784-793.
125. Fournet-Dulguerov N, MacLusky NJ, Leranth CZ, Todd R, Mendelson CR, Simpson ER, Naftolin F. Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. J Clin Endocrinol Metab. 1987;65(4):757-764.
126. Kumar P, Luo Y, Tudela C, Alexander JM, Mendelson CR. The c- Myc-regulated microRNA-17-92 (miR-17-92) and miR- 106a-363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol. 2013;33(9): 1782-1796.
127. Jiang B, Mendelson CR. USF1 and USF2 mediate inhibition of human trophoblast differentiation and CYP19 gene expression by Mash-2 and hypoxia. Mol Cell Biol. 2003;23(17):6117-6128.
128. Charles SM, Julian CG, Vargas E, Moore LG. Higher estrogen levels during pregnancy in Andean than European residents of high altitude suggest differences in aromatase activity. J Clin Endocrinol Metab. 2014;99(8):2908-2916.
129. H¨ahnel ME, Martin JD, Michael CA, H¨ahnel R. Metabolism of androstenedione by placental microsomes in pregnancy hypertension. Clin Chim Acta. 1989;181(1):103-108.
130. Shimodaira M, Nakayama T, Sato I, Sato N, Izawa N, Mizutani Y, Furuya K, Yamamoto T. Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy. Endocrine. 2012;42(3):700-707.
131. Moon J-Y, Moon MH, Kim KT, Jeong DH, Kim YN, Chung BC, Choi MH. Cytochrome P450-mediated metabolic alterations in preeclampsia evaluated by quantitative steroid signatures. J Steroid Biochem Mol Biol. 2014;139:182-191.
132. Perez-Sepulveda A, Monteiro LJ, Dobierzewska A, España-Perrot PP, Venegas-Araneda P, Guzmán-Rojas AM, Gonzalez MI, Palominos-Rivera M, Irarrazabal CE, Figueroa-Diesel H, Varas- Godoy M, Illanes SE. Placental aromatase is deficient in placental ischemia and preeclampsia. PloS One. 2015;10(10):e0139682.
133. Moore SC, Matthews CE, Ou ShuX, Yu K, GailMH, XuX, Ji B-T, Chow W-H, Cai Q, Li H, Yang G, Ruggieri D, Boyd-Morin J, Rothman N, Hoover RN, Gao Y-T, Zheng W, Ziegler RG. Endogenous estrogens, estrogen metabolites, and breast cancer risk in postmenopausal Chinese women. J Natl Cancer Inst. 2016; 108(10):djw103 .
134. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM. Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005;65(23):11071-11082.
135. Bulun SE. Aromatase and estrogen receptor a deficiency. Fertil Steril. 2014;101(2):323-329.
136. Hauri-Hohl A, Meyer-Böni M, Lang-Muritano M, Hauri-Hohl M, Schoenle EJ, Biason-Lauber A. Aromatase deficiency owing to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene. Clin Endocrinol (Oxf). 2011;75(1):39-43.
137. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab. 1997;82(6):1739-1745.
138. Ludwikowski B, Heger S, Datz N, Richter-Unruh A, Gonźalez R. Aromatase deficiency: rare cause of virilization. Eur J Pediatr Surg. 2013;23(5):418-422.
139. Maliqueo M, EchiburúB, Crisosto N. Sex steroids modulate uterine-placental vasculature: implications for obstetrics and neonatal outcomes. Front Physiol. 2016;7:152.
140. Sieveking DP, Lim P, Chow RWY, Dunn LL, Bao S, McGrath KCY, Heather AK, Handelsman DJ, Celermajer DS, Ng MKC. A sex-specific role for androgens in angiogenesis. J Exp Med. 2010; 207(2):345-352.
141. Henríquez S, Kohen P, Xu X, Veenstra TD, Muñoz A, Palomino WA, Strauss JF III, Devoto L. Estrogen metabolites in human corpus luteum physiology: differential effects on angiogenic activity. Fertil Steril. 2016;106(1):230-237.e1.
142. Rabe T, Hösch R, Runnebaum B. Sulfatase deficiency in the human placenta: clinical findings. Biol Res Pregnancy Perinatol. 1983;4(3):95-102.
143. Ishibashi O, Ohkuchi A, Ali MM, Kurashina R, Luo S-S, Ishikawa T, Takizawa T, Hirashima C, Takahashi K, Migita M, Ishikawa G, Yoneyama K, Asakura H, Izumi A, Matsubara S, Takeshita T, Takizawa T. Hydroxysteroid (17-b) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: a novel marker for predicting preeclampsia. Hypertension. 2012;59(2):265-273.
144. Ohkuchi A, Ishibashi O, Hirashima C, TakahashiK, Matsubara S, Takizawa T, Suzuki M. Plasma level of hydroxysteroid (17-b) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1/placental growth factor ratio. Hypertens Res. 2012;35(12):1152-1158.
145. Li Y, Isomaa V, Pulkka A, Herva R, Peltoketo H, Vihko P. Expression of 3beta-hydroxysteroid dehydrogenase type 1, P450 aromatase, and 17beta-hydroxysteroid dehydrogenase types 1, 2, 5 and 7 mRNAs in human early and mid-gestation placentas. Placenta. 2005;26(5):387-392.
146. Saloniemi T, Jokela H, Strauss L, Pakarinen P, Poutanen M. The diversity of sex steroid action: novel functions of hydroxysteroid (17b) dehydrogenases as revealed by genetically modified mouse models. J Endocrinol. 2012;212(1):27-40.
147. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27(2):135-206.
148. Tenhunen J, Salminen M, Jalanko A, Ukkonen S, Ulmanen I. Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol. 1993; 12(3):253-263.
149. Salih SM, Salama SA, Fadl AA, Nagamani M, Al-Hendy A. Expression and cyclic variations of catechol-O-methyl transferase in human endometrial stroma. Fertil Steril. 2008;90(3):789-797.
150. Salama SA, Jamaluddin M, Kumar R, Hassan MH, Al-Hendy A. Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: distinct effect of progesterone receptor isoforms. J Steroid Biochem Mol Biol. 2007;107(3-5): 253-261.
151. Liang S, Liu X, Fan P, Liu R, Zhang J, He G, Liu Y, Bai H. Association between Val158Met functional polymorphism in the COMT gene and risk of preeclampsia in a Chinese population. Arch Med Res. 2012;43(2):154-158.
152. Lim JH, Kim SY, Kim DJ, Park SY, Han HW, Han JY, Lee SW, Yang JH, Ryu HM. Genetic polymorphism of catechol-Omethyltransferase and cytochrome P450c17a in preeclampsia. Pharmacogenet Genomics. 2010;20(10):605-610.
153. Hill LD, York TP, Kusanovic JP, Gomez R, Eaves LJ, Romero R, Strauss JF III. Epistasis betweenCOMTand MTHFRin maternalfetal dyads increases risk for preeclampsia. PloS One. 2011;6(1): e16681.
154. Roten LT, Fenstad MH, Forsmo S, Johnson MP, Moses EK, Austgulen R, Skorpen F. A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2). Mol Hum Reprod. 2011;17(7):439-446.
155. Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catecholo- methyl transferase activity in the human term placenta. Am J Perinatol. 1988;5(2):121-127.
156. Palmer K, Saglam B, Whitehead C, Stock O, Lappas M, Tong S. Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression.AmJ Pathol. 2011;178(6):2484-2488.
157. Grouzmann E, Cavadas C, Grand D, Moratel M, Aubert J-F, Brunner HR, Mazzolai L. Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice. Pflugers Arch. 2003;447(2):254-258.
158. Böttner M, Thelen P, Jarry H. Estrogen receptor beta: tissue distribution and the still largely enigmatic physiological function. J Steroid Biochem Mol Biol. 2014;139:245-251.
159. Chakraborty S, Willett H, Biswas PK. Insight into estrogen receptor beta-beta and alpha-beta homo- and heterodimerization: a combined molecular dynamics and sequence analysis study. Biophys Chem. 2012;170:42-50.
160. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346(5):340-352.
161. Kuiper GG, Carlsson B, Grandien K, Enmark E, H¨aggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863-870.
162. Helguero LA, Faulds MH, Gustafsson J-A, Haldosén L-A. Estrogen receptors alfa (Eralpha) and beta (Erbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44): 6605-6616.
163. Gustafsson JA, Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol. 2000;74(5):245-248.
164. Gustafsson JA. Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol. 1999;163(3):379-383.
165. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update. 2000;6(3):225-236.
166. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF, Korach KS. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA. 1996;93(22):12626-12630.
167. Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G, Singh R, Bhasin S, Jasuja R. The dynamic structure of the estrogen receptor. J Amino Acids. 2011;2011:812540.
168. Gruber CJ, Gruber DM, Gruber IML, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab. 2004;15(2):73-78.
169. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res. 1988;16(2):647-663.
170. Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem. 2005; 280(1):347-354.
171. Heldring N, Isaacs GD, Diehl AG, Sun M, Cheung E, Ranish JA, Kraus WL. Multiple sequence-specific DNA-binding proteins mediate estrogen receptor signaling through a tethering pathway. Mol Endocrinol. 2011;25(4):564-574.
172. Barnea ER, MacLusky NJ, Naftolin F. Kinetics of catechol estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids. 1983;41(5):643-656.
173. Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17betaestradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol. 1998;67(5-6):413-419.
174. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem. 1984;259(8):4840-4845.
175. Martucci CP, Fishman J. Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology. 1979;105(6):1288-1292.
176. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994;368(6468):237-239.
177. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399(6736):601-605.
178. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales- Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3- kinase-Akt pathway in human endothelial cells. Circ Res. 2000; 87(8):677-682.
179. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV, Sanz M-J. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res. 2002;91(12):1142-1150.
180. Jobe SO, Ramadoss J, Wargin AJ, Magness RR. Estradiol-17b and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites selectively stimulate production of prostacyclin in uterine artery endothelial cells: role of estrogen receptor-a versus estrogen receptor-b. Hypertension. 2013;61(2):509-518.
181. Padayachi T, Pegoraro RJ, Rom L, Joubert SM. Enzyme immunoassay of oestrogen and progesterone receptors in uterine and intrauterine tissue during human pregnancy and labour. J Steroid Biochem Mol Biol. 1990;37(4):509-511.
182. Perrot-Applanat M, Deng M, Fernandez H, Lelaidier C, Meduri G, Bouchard P. Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. J Clin Endocrinol Metab. 1994;78(1):216-224.
183. Rossmanith WG, Wolfahrt S, Ecker A, Eberhardt E. The demonstration of progesterone, but not of estrogen, receptors in the developing human placenta. Horm Metab Res. 1997;29(12): 604-610.
184. Taddei G, Noei I, Periti E, Borri P, Torricelli F, Tozzi P, Moncini D, Paglierani M, Branconi F. Chorion villosum does not express progesterone and estrogen receptors during the first trimester of pregnancy. Gynecol Obstet Invest. 1996;42(2):77-79.
185. Wu WX, Ma XH, Smith GC, Nathanielsz PW. Differential distribution of Eralpha and Erbeta mRNA in intrauterine tissues of the pregnant rhesus monkey. Am J Physiol Cell Physiol. 2000; 278(1):C190-C198.
186. Bukovsky A, Cekanova M, Caudle MR, Wimalasena J, Foster JS, Henley DC, Elder RF. Expression and localization of estrogen receptor-alpha protein in normal and abnormal term placentae and stimulation of trophoblast differentiation by estradiol. Reprod Biol Endocrinol. 2003;1:13.
187. Bukovsky A, CaudleMR, CekanovaM, Fernando RI, Wimalasena J, Foster JS, HenleyDC, ElderRF. Placental expression of estrogen receptor beta and its hormone binding variant-comparison with estrogen receptor alpha and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells. Reprod Biol Endocrinol. 2003;1:36.
188. Younes MA, Besch NF, Besch PK. Estradiol and progesterone binding in human term placental cytosol. Am J Obstet Gynecol. 1981;141(2):170-174.
189. Dasgupta C, Chen M, Zhang H, Yang S, Zhang L. Chronic hypoxia during gestation causes epigenetic repression of the estrogen receptor-a gene in ovine uterine arteries via heightened promoter methylation. Hypertension. 2012;60(3):697-704.
190. Tessier C, Deb S, Prigent-Tessier A, Ferguson-Gottschall S, Gibori GB, Shiu RP, Gibori G. Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin. Endocrinology. 2000;141(10): 3842-3851.
191. Welsh T, Johnson M, Yi L, Tan H, Rahman R, Merlino A, Zakar T, Mesiano S. Estrogen receptor (ER) expression and function in the pregnant human myometrium: estradiol via ERa activates ERK1/2 signaling in term myometrium. J Endocrinol. 2012; 212(2):227-238.
192. Pastore MB, Jobe SO, Ramadoss J, Magness RR. Estrogen receptor- a and estrogen receptor-b in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow. Semin Reprod Med. 2012;30(1):46-61.
193. Byers MJ, Zangl A, Phernetton TM, Lopez G, Chen D-B, Magness RR. Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of Eralpha and Erbeta levels. J Physiol. 2005;565(Pt 1):85-99.
194. Molvarec A, Vér A, Fekete A, Rosta K, Derzbach L, Derzsy Z, Karádi I, RigóJ, Jr. Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res. 2007;30(3):205-211.
195. Zhang J, Bai H, Liu X, Fan P, Liu R, Huang Y, Wang X, He G, Liu Y, Liu B. Genotype distribution of estrogen receptor alpha polymorphisms in pregnant women from healthy and preeclampsia populations and its relation to blood pressure levels. Clin Chem Lab Med. 2009;47(4):391-397.
196. Cudmore MJ, Hewett PW, Ahmad S, Wang K-Q, Cai M, Al-Ani B, Fujisawa T, Ma B, Sissaoui S, Ramma W, Miller MR, Newby DE, Gu Y, Barleon B, Weich H, Ahmed A. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun. 2012;3:972.
197. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA. 2000;97(20):10972-10977.
198. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol. 2000;279(5):H2033-H2042.
199. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91(3):755-763.
200. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21(1):6-12.
201. Rauschemberger MB, SandovalMJ, Massheimer VL. Cellular and molecular actions displayed by estrone on vascular endothelium. Mol Cell Endocrinol. 2011;339(1-2):136-143.
202. Holmes DIR, Zachary I. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett. 2004;557(1- 3):93-98.
203. Menendez D, Inga A, Snipe J, Krysiak O, Schönfelder G, Resnick MA. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol. 2007;27(7):2590-2600.
204. Gargett CE, Zaitseva M, Bucak K, Chu S, Fuller PJ, Rogers PAW. 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: role of estrogen receptor-alpha and -beta. J Clin Endocrinol Metab. 2002;87(9):4341-4349.
205. Hou HH, Cheng SL, Liu HT, Yang FZ, Wang HC, Yu CJ. Elastase induced lung epithelial cell apoptosis and emphysema through placenta growth factor. Cell Death Dis. 2013;4:e793.
206. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGFdependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010; 17(3):499-512.
207. Jaffer S, Shynlova O, Lye S. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. Endocrinology. 2009;150(10):4672-4680.
208. Shynlova O, Tsui P, Dorogin A, Langille BL, Lye SJ. Insulin-like growth factors and their binding proteins define specific phases of myometrial differentiation during pregnancy in the rat. Biol Reprod. 2007;76(4):571-578.
209. Shynlova O, Tsui P, Jaffer S, Lye SJ. Integration of endocrine and mechanical signals in the regulation of myometrial functions during pregnancy and labour. Eur J Obstet Gynecol Reprod Biol. 2009;144(Suppl 1):S2-S10.
210. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3(4): 363-375.
211. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613.
212. Perez-Sepulveda A, España-Perrot PP, Norwitz ER, Illanes SE. Metabolic pathways involved in 2-methoxyestradiol synthesis and their role in preeclampsia. Reprod Sci. 2013;20(9):1020-1029.
213. Thaler I, Manor D, Itskovitz J, Rottem S, Levit N, Timor-Tritsch I, Brandes JM. Changes in uterine blood flow during human pregnancy. Am J Obstet Gynecol. 1990;162(1):121-125.
214. Mabie WC, DiSessa TG, Crocker LG, Sibai BM, Arheart KL. A longitudinal study of cardiac output in normal human pregnancy. Am J Obstet Gynecol. 1994;170(3):849-856.
215. Mone SM, Sanders SP, Colan SD. Control mechanisms for physiological hypertrophy of pregnancy. Circulation. 1996;94(4): 667-672.
216. Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine. 2002;18(3):239-245.
217. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:
218. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:
219. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol Heart Circ Physiol. 2001;280(4):H1699-H1705.
220. Rupnow HL, Phernetton TM, Modrick ML, Wiltbank MC, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VIII. Estrogen and progesterone effects on cPLA2, COX-1, and PGIS protein expression. Biol Reprod. 2002; 66(2):468-474.
221. Resnik R, Killam AP, Battaglia FC, Makowski EL, Meschia G. The stimulation of uterine blood flow by various estrogens. Endocrinology. 1974;94(4):1192-1196.
222. BarbagalloM, Dominguez LJ, Licata G, Shan J, Bing L, Karpinski E, Pang PKT, Resnick LM. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension. 2001;37(1): 142-147.
223. Miller SL, Jenkin G, Walker DW. Effect of nitric oxide synthase inhibition on the uterine vasculature of the late-pregnant ewe. Am J Obstet Gynecol. 1999;180(5):1138-1145.
224. Magness RR, Sullivan JA, Li Y, Phernetton TM, Bird IM. Endothelial vasodilator production by uterine and systemic arteries. VI. Ovarian and pregnancy effects on eNOS and NO(x). Am J Physiol Heart Circ Physiol. 2001;280(4):H1692-H1698.
225. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM. Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy. Circ Res. 2000;87(5):406-411.
226. Storment JM, Meyer M, Osol G. Estrogen augments the vasodilatory effects of vascular endothelial growth factor in the uterine circulation of the rat. Am J Obstet Gynecol. 2000;183(2): 449-453.
227. Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol. 2003;50(1):49-59.
228. Montgomery S, Shaw L, Pantelides N, Taggart M, Austin C. Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br J Pharmacol. 2003;139(7):1249-1253.
229. Salom JB, Burguete MC, Pérez-Asensio FJ, Torregrosa G, Alborch E. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition. J Cereb Blood Flow Metab. 2001;21(4):422-429.
230. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286(2): R233-R249.
231. Stefano GB, Prevot V, Beauvillain JC, Cadet P, Fimiani C, Welters I, Fricchione GL, Breton C, Lassalle P, Salzet M, Bilfinger TV. Cellsurface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation. 2000;101(13):1594-1597.
232. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol. 1997;272(6 Pt 2):H2765-H2773.
233. Clewell WH, Carson BA, Meschia G. Comparison of uterotrophic and vascular effects of estradiol-17beta and estriol in the mature organism. Am J Obstet Gynecol. 1977;129(4):384-388.
234. Levine MG, Miodovnik M, Clark KE. Uterine vascular effects of estetrol in nonpregnant ewes. Am J Obstet Gynecol. 1984;148(6): 735-738.
235. Hilgers RHP, Oparil S, Wouters W, Coelingh Bennink HJT. Vasorelaxing effects of estetrol in rat arteries. J Endocrinol. 2012; 215(1):97-106.
236. Berg D, Thaler F, Kuss E. Concentrations of 2-hydroxyoestrogens in human sera measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1982;100(1): 154-160.
237. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983;103(2):282-288.
238. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol. 2010;176(2): 710-720.
239. Dubey RK, Jackson EK. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab. 2009;20(8):374-379.
240. Lobmaier SM, Figueras F, Mercade I, Crovetto F, Peguero A, Parra-Saavedra M, Ortiz JU, Crispi F, Gratacós E. Levels of maternal serum angiogenic factors in third-trimester normal pregnancies: reference ranges, influence of maternal and pregnancy factors and fetoplacental Doppler indices. Fetal Diagn Ther. 2014;36(1):38-43.
241. Baggia S, Albrecht ED, Pepe GJ. Regulation of 11 betahydroxysteroid dehydrogenase activity in the baboon placenta by estrogen. Endocrinology. 1990;126(5):2742-2748.
242. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA. 1983;80(19): 6056-6060.
243. Schoof E, GirstlM, FrobeniusW, KirschbaumM, DörrHG, Rascher W, Dötsch J. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab. 2001;86(3):1313-1317.
244. He P, Chen Z, Sun Q, Li Y, Gu H, Ni X. Reduced expression of 11b-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARg but increased PPARa expression. Endocrinology. 2014;155(1):299-309.
245. Dahlstrøm B, Romundstad P, Øian P, Vatten LJ, Eskild A. Placenta weight in pre-eclampsia. Acta Obstet Gynecol Scand. 2008; 87(6):608-611.
246. Pepe GJ, Albrecht ED. Comparison of cortisol-cortisone interconversion in vitro by the human and baboon placenta. Steroids. 1984;44(3):229-240.
247. Doody KM, Carr BR, Rainey WE, Byrd W, Murry BA, Strickler RC, Thomas JL, Mason JI. 3 beta-hydroxysteroid dehydrogenase/ isomerase in the fetal zone and neocortex of the human fetal adrenal gland. Endocrinology. 1990;126(5):2487-2492.
248. Kaludjerovic J, Ward WE. The interplay between estrogen and fetal adrenal cortex. J Nutr Metab. 2012;2012:837901.
249. Albrecht ED, Babischkin JS, Davies WA, Leavitt MG, Pepe GJ. Identification and developmental expression of the estrogen receptor alpha and beta in the baboon fetal adrenal gland. Endocrinology. 1999;140(12):5953-5961.
250. Albrecht ED, Aberdeen GW, Pepe GJ. Estrogen elicits cortical zone-specific effects on development of the primate fetal adrenal gland. Endocrinology. 2005;146(4):1737-1744.
251. Bramham K, Nelson-Piercy C, Gao H, Pierce M, Bush N, Spark P, Brocklehurst P, Kurinczuk JJ, Knight M. Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol. 2013;8(2):290-298.
252. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-241.
253. Roberts JM, Bodnar LM, Patrick TE, Powers RW. The role of obesity in preeclampsia. Pregnancy Hypertens. 2011;1(1):6-16.
254. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443-477.
255. Turgut A, Ozler A, Goruk NY, Tunç SY, Sak ME, Evsen MS, Evliyaoglu O, Gul T. Serum levels of the adipokines, free fatty acids, and oxidative stress markers in obese and non-obese preeclamptic patients. Clin Exp Obstet Gynecol. 2015;42(4): 473-479.
256. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939-949.
257. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10(1):19-29.
258. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745-E751.
259. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-1801.
260. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf). 2012;76(1):2-11.
261. Palei AC, Spradley FT, Granger JP. Chronic hyperleptinemia results in the development of hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2015;308(10):R855-R861.
262. Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol. 1996;10(11):1350-1357.
263. Higgins L, Mills TA, Greenwood SL, Cowley EJ, Sibley CP, Jones RL. Maternal obesity and its effect on placental cell turnover. J Matern Fetal Neonatal Med. 2013;26(8):783-788.
264. Haider S, Knöfler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009;30(2):111-123.
265. Garcia-Lloret MI, Winkler-Lowen B, Guilbert LJ. Monocytes adhering by LFA-1 to placental syncytiotrophoblasts induce local apoptosis via release of TNF-alpha. A model for hematogenous initiation of placental inflammations. J Leukoc Biol. 2000;68(6): 903-908.
266. Coya R, Martul P, Algorta J, Aniel-Quiroga MA, Busturia MA, Señarís R. Effect of leptin on the regulation of placental hormone secretion in cultured human placental cells. Gynecol Endocrinol. 2006;22(11):620-626.
267. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(Suppl 1):S5-S10.
268. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64(12):1629-1639.
269. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesityrelated inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm. 2013;2013:139239.
270. Desoye G, Hauguel-de Mouzon S. The human placenta in gestational diabetes mellitus. The insulin and cytokine network. Diabetes Care. 2007;30(Suppl 2):S120-S126.
271. McRobie DJ, Korzekwa KR, Glover DD, Tracy TS. The effects of diabetes on placental aromatase activity. J Steroid Biochem Mol Biol. 1997;63(1-3):147-153.
272. Uzelac PS, Li X, Lin J, Neese LD, Lin L, Nakajima ST, Bohler H, Lei Z. Dysregulation of leptin and testosterone production and their receptor expression in the human placenta with gestational diabetes mellitus. Placenta. 2010;31(7):581-588.
273. MorissetA-S, DubéM-C, DroletR, PelletierM, Labrie F, Luu-TheV, Tremblay Y, Robitaille J, John Weisnagel S, Tchernof A. Androgens in the maternal and fetal circulation: association with insulin resistance. J Matern Fetal Neonatal Med. 2013;26(5):513-519.
274. Nestler JE. Modulation of aromatase and P450 cholesterol sidechain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I. Endocrinology. 1987;121(5):1845-1852.
275. Nestler JE. Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II. J Steroid Biochem Mol Biol. 1993;44(4-6):449-457.
276. Schneider HJ, Friedrich N, Klotsche J, Schipf S, NauckM, Völzke H, Sievers C, Pieper L, M¨arz W, Wittchen H-U, Stalla GK, Wallaschofski H. Prediction of incident diabetes mellitus by baseline IGF1 levels. Eur J Endocrinol. 2011;164(2):223-229.
277. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129(11):1254-1261.
278. Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, Kanbay M. Hypertension as an autoimmune and inflammatory disease. Hypertens Res. 2016;39(8):567-573 .
279. Stanfill A, Bloodworth R, Cashion A. Lessons learned: experiences of gaining weight by kidney transplant recipients. Prog Transplant. 2012;22(1):71-78.
280. Azancot MA, Ramos N, Torres IB, García-Carro C, Romero K, Espinel E, Moreso F, Seron D. Inflammation and atherosclerosis are associated with hypertension in kidney transplant recipients. J Clin Hypertens (Greenwich). 2015;17(12):963-969.
281. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12(4):358-362.
282. Hewitt DP, Mark PJ, Waddell BJ. Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. Endocrinology. 2006;147(12):5568-5574.
283. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85(2):134-138.
284. Chiasson VL, Talreja D, Young KJ, Chatterjee P, Banes-Berceli AK, Mitchell BM. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension. Hypertension. 2011;57(6):1167-1175.
285. Djordjević NZ, Babić GM, Marković SD, Ognjanović BI, Stajn AS, Saicić ZS. The antioxidative effect of estradiol therapy on erythrocytes in women with preeclampsia. Reprod Toxicol. 2010; 29(2):231-236.
286. Pisani SL, Neese SL, Doerge DR, Helferich WG, Schantz SL, Korol DL. Acute genistein treatment mimics the effects of estradiol by enhancing place learning and impairing response learning in young adult female rats. Horm Behav. 2012;62(4):491-499.
287. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER.Gprotein-coupled estrogen receptorselective ligands modulate endometrial tumor growth. Obstet Gynecol Int. 2013;2013:472720.
288. Fernandez AR, Omar SZ, Husain R. Role of Genistein in Preeclampsia: A Case-Control Study. J Reprod Med. 2016;61(1-2): 47-51.